Researchers sought to determine whether conditioning chemotherapy containing alemtuzumab may improve outcomes for GVHD in pediatric patients with hematologic malignancies.
An international, retrospective study was conducted to assess outcomes following alloHCT after PD-1 blockade in Hodgkin lymphoma.
Glycopeptide antibiotic therapy may be linked to risk of extensive chronic graft-versus-host disease after allogeneic stem cell transplantation.
Researchers sought to determine whether adding abatacept to standard prophylaxis may reduce rates of GVHD in patients with beta-thalassemia.
Researchers have sought to determine the monetary cost of specific aGVHD staging and organ involvement for patients who receive HSCT, a topic which remains poorly understood.
Ruxolitinib, a selective nonreceptor Janus kinase 1/2 inhibitor shown to have activity in adults with refractory GVHD, was studied in pediatric patients.
Study authors retrospectively evaluated effect of thymoglobulin addition in RIC and MAC regimens on the cumulative incidence and severity of acute and chronic GVHD, overall survival, and relapse rate in adult AML patients who underwent URD PBSCT.
A team of investigators sought to determine the ability of abatacept to decrease the risk of severe acute graft-vs-host disease in patients undergoing unrelated donor allogeneic hematopoietic cell transplant.
